Their research results include that miR-22 effectively inhibits tumor growth and metastasis by targeting and inhibiting ATP citrate lyase (ACLY), providing potential therapeutic benefits for osteosarcoma, prostate cancer, cervical cancer, and lung cancer (56). The gene discussed is ACLY; the disease is lung carcinoma.